Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic-Resistant Bacteria
Shots:
- Biomica collaborated with Weizmann Institute of Science to develop a selective treatment against antibiotic-resistant strains of Staphylococcus aureus infection- targeting a specific microbe while maintaining the microbiome of the patients' gut.
- Biomica has in-licensed IP rights of Prof. Ada E. Yonath’s work and discoveries in the high-resolution crystal structure- allowing a high degree of specificity with Biomica's computational technology- enabling the development of selective- narrow-spectrum antibiotics
- The collaboration will put Prof. Yonath's achievements into practice- to resolve a substantial- unmet clinical need- by developing a highly selective solution to the resistance of Staphylococcus aureus
Click here to read full press release/ article | Ref: PRNewswire | Image: Linkedin
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com